前收市價 | 9.27 |
開市 | 9.40 |
買盤 | 9.58 x 300 |
賣出價 | 9.62 x 1200 |
今日波幅 | 9.26 - 9.81 |
52 週波幅 | 1.76 - 15.40 |
成交量 | |
平均成交量 | 5,220,991 |
市值 | 1.103B |
Beta 值 (5 年,每月) | 1.15 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -3.78 |
業績公佈日 | 2024年5月07日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 18.00 |
Arcutis Biotherapeutics, Inc. (ARQT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 54.8% in Arcutis Biotherapeutics, Inc. (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.